Tumor pO2 as a Surrogate Marker to Identify Therapeutic Window During Metronomic Chemotherapy of 9L Gliomas

Advances in Experimental Medicine and Biology - United States
doi 10.1007/978-1-4419-7756-4_15
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer US

Related search

Apelin as a Marker for Monitoring the Tumor Vessel Normalization Window During Antiangiogenic Therapy

Cancer Science
Cancer ResearchMedicineOncology
2015English

Radiotherapy-Assisted Tumor Selective Metronomic Oral Chemotherapy

International Journal of Cancer
Cancer ResearchOncology
2017English

Effect of Perfluorochemicals on BCNU Chemotherapy in a 9L Rat Brain Tumor Model

Neurologia Medico-Chirurgica
SurgeryNeurology
1982English

Resistance to Metronomic Chemotherapy and Ways to Overcome It

Cancer Letters
Cancer ResearchOncology
2017English

A Model to Investigate the Feasibility of FDG as a Surrogate Marker of Hypoxia

2007English

Metronomic Chemotherapy in Metastatic Breast Cancer

Novel Research in Sciences
2019English

Anti-Tumor Innate Immunity Activated by Intermittent Metronomic Cyclophosphamide Treatment of 9L Brain Tumor Xenografts Is Preserved by Anti-Angiogenic Drugs That Spare VEGF Receptor 2

Molecular Cancer
Cancer ResearchOncologyMolecular Medicine
2014English

KIM-1 as a Potential Serological/Urinological Tumor-Associated Marker of Renal Cell Carcinoma and Chemotherapy Nephrotoxicity

Onkourologiya
OncologyRadiologyUrologyNuclear MedicineNephrologyImagingSurgery
2019English

Intravital Imaging Tumor Screen Used to Identify Novel Metastasis-Blocking Therapeutic Targets

Cell Stress
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy